For patients and families managing essential tremor or Parkinson's disease, the question that matters most is not how a device works in theory — it is whether it makes a meaningful difference to real daily life. Two studies on the Steadi-3 Plus now provide a clear answer, and the results are worth understanding in detail.
The two studies
The first was a controlled performance evaluation conducted by Steadiwear Inc. in February 2025. Nine patients with upper-limb tremor from either essential tremor or Parkinson's disease took part in a single-blind, placebo-controlled study in which a blinded neurologist used the Fahn-Tolosa-Marín (FTM) scale — the gold standard for rating tremor severity — to assess performance across a series of daily tasks. The results were significant: 80 percent of participants showed improvement compared to no intervention, and 70 percent showed improvement compared to a placebo device. The mean reduction in FTM tremor scores ranged from 35 to 53 percent depending on the task, with statistical analysis confirming the effect was not due to chance. No adverse events were recorded in any patient.
The second was a real-world evidence survey of 54 patients using the device across eight activities of daily living, also assessed using a modified FTM scale. This study, submitted for peer review in 2025, looked at what actually happened when people used the device in their everyday lives — not in a controlled clinical setting.
The headline finding
Seventy percent of participants retained the device long term. And every single one of those 38 patients experienced at least 59 percent estimated tremor power reduction across core daily activities including eating, drinking, writing, pouring, and using small tools and objects. That figure is not an average — it is the floor. Stronger responders, approximately one in two among those who kept the device, achieved estimated tremor power reductions of between 75 and 90 percent. For writing specifically, that figure reached 85 to 87 percent in the strongest responders.
The patients who returned the device showed near-zero improvement across every task assessed. This responder/non-responder pattern has a direct clinical implication: a brief trial period reliably identifies who will benefit. Early response predicts long-term adoption.
Why these specific tasks matter
The activities measured in the study are not arbitrary. Drinking from a cup happens at every meal and every medication dose — it cannot be scheduled around a therapy session. Eating occurs three times a day in any setting. Writing and signing documents — medical consent forms, legal paperwork — arrive unexpectedly. Pouring hot liquids carries a genuine safety risk when tremor is severe. These are the moments where functional independence is at stake, and they cannot wait for a calibration procedure or the onset of pharmacological effect.
How the device works
The Steadi-3 Plus uses a passive magnetic damping system that reduces the physical expression of tremor at the wrist — no electricity, no programming, no calibration required. It activates above 2 Hz, covering the full frequency ranges of both essential tremor (4 to 12 Hz) and Parkinson's tremor (3 to 6 Hz). Voluntary movement is unaffected.
It is an FDA-registered Class I medical device with zero adverse events recorded across all patients in both studies. It can be used alongside any pharmacotherapy, and — uniquely — can be used concurrently with other tremor management approaches including session-based neuromodulation, with no contraindications.
About Pisces Innovation
At Pisces Innovation, we are the exclusive authorised US distributor of the Steadi-3 Plus. If you would like to discuss whether it is appropriate for you or a family member, or if you are a clinician interested in trial materials, our team is here to help.

(888) 828-7868